The last portion of Dr. Leighl's program on "Highlights of Lung Cancer from 2012" covered maintenance therapy, specifically focusing on the latest report of results from the PARAMOUNT trial, which demonstrated a significant survival benefit for maintenance Alimta (pemetrexed) continued after four cycles of the first line combination of cisplatin and Alimta.

Dr. Alan Sandler, Oregon Health and Science University, considers the various options for maintenance therapy as well as a potential treatment break after first line treatment of advanced non-small cell lung cancer.

[powerpress]

Last year, the PARAMOUNT trial was one of the highlight presentations in lung cancer from ASCO 2011, an important landmark study of continuation maintenance therapy with Alimta (pemetrexed).